The company will carry out a reverse stock split in a ratio of 1:125. The share will be traded under new ISIN code with effect from Oct 17, 2025. The order book will not change.
| Short name: | XBRANE |
| Terms: | Reverse split: 1:125 |
| Current ISIN: | SE0007789409 |
| Last day of trading with current ISIN code: | Oct 16, 2025 |
| New ISIN code: | SE0026598583 |
| First day of trading with new ISIN code: | Oct 17, 2025 |
Nasdaq Stockholm AB, Issuer Surveillance, dl-ilasto@nasdaq.com, +46 8 405 7280
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04.11. | Xbrane Biopharma AB: First patient included in Xdivane pivotal clinical trial | Xbrane Biopharma AB (publ) ("Xbrane") (Nasdaq Stockholm: XBRANE) today announce that the first patient has been included in the pivotal clinical trial for Xdivane (nivolumab biosimilar candidate).
As... ► Artikel lesen | |
| 28.10. | Xbrane Biopharma AB: Siavash Bashiri sells shares to repay loan taken in connection with the 2024 rights issue, but remains a dedicated and long-term employee and shareholder | Xbrane Biopharma AB (publ) ("Xbrane" or "the Company") (Nasdaq Stockholm: XBRANE) announces that Siavash Bashiri of Xbrane's management team have sold shares to pay back a loan that was taken in connection... ► Artikel lesen | |
| 24.10. | Xbrane Biopharma AB: Xbrane Biopharma releases Interim Report for January-September 2025 | Xbrane Biopharma AB's (publ.) ("Xbrane") Interim Report for January-September 2025, is as of today, available on the Company's website, https://xbrane.com/.
FINANCIAL OVERVIEWTHIRD QUARTER 2025*• Revenue... ► Artikel lesen | |
| 20.10. | XFRA NEW INSTRUMENTS AVAILABLE ON 20.10.2025 | The following instruments on XETRA do have their first trading 20.10.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 20.10.2025
Aktien
1 AU0000177172 iTech Minerals Ltd.
2... ► Artikel lesen | |
| 19.10. | Xbrane Biopharma AB: Xbrane provides Regulatory update on FDA review of its ranibizumab biosimilar candidate | Xbrane Biopharma AB ("Xbrane"), a leading Swedish biosimilar developer, announce that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to the Company's Biologics... ► Artikel lesen |
